Teva faces generic industry competition pressure, generic Copaxone risk, and financial leverage.
Teva Pharmaceutical continues to face significant challenges in both its generics and branded drug operations. The generics segment faced significantly more margin erosion than we anticipated, thanks to ongoing pricing pressure in the U.S. market from new entrants, increased customer buying power, and competition on key products. As a result, management once again lowered its year-end outlook to $3.77-$3.87 in adjusted earnings per share (below our estimate of $4.06). We plan to revisit our assu...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.